Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01459653 · OUTCOME

Type of EP2006 Prophylaxis

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor · Source last updated 2016-01-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days

What was measured

Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.

Analysis population: Delayed Primary: EP2006 initiated in cycle 2 or later with no CIN/FN in prior cycle. True secondary: EP2006 initiated in cycle 2 or later following CIN/FN in prior cycle.

Groups in this outcome

EP2006

Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
EP20061447

Reported measurements

Primary (initiated in cycle1)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP20061046Not reportedNot reportedNot reportedNot reported
Secondary (initiated in cycle2 or later)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006401Not reportedNot reportedNot reportedNot reported
Delayed primary
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006245Not reportedNot reportedNot reportedNot reported
True secondary
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006156Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1046
    title
    Primary (initiated in cycle1)
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        401
    title
    Secondary (initiated in cycle2 or later)
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        245
    title
    Delayed primary
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        156
    title
    True secondary
denoms
  1. counts
    1. group Id
      OG000
      value
      1447
    units
    Participants
description
Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.
groups
  1. description
    Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
    id
    OG000
    title
    EP2006
param Type
NUMBER
population Description
Delayed Primary: EP2006 initiated in cycle 2 or later with no CIN/FN in prior cycle. True secondary: EP2006 initiated in cycle 2 or later following CIN/FN in prior cycle.
reporting Status
POSTED
time Frame
All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days
title
Type of EP2006 Prophylaxis
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice